ezetimibe has been researched along with Body Weight in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, C; Lu, P; Qin, H; Wang, Y; Xue, X; Yuan, X; Zhang, Q | 1 |
| Ikeda, T; Iwatani, Y; Kamisako, T; Kishino, Y; Ogawa, H; Tanaka, Y; Yamamoto, K | 1 |
| Kumata, N; Osada, K; Terunuma, S | 1 |
| Chuang, JC; Lopez, AM; Posey, KS; Turley, SD | 1 |
| Chen, Y; Li, WX; Liu, Y; Ma, Y; Song, ZY; Sun, WW; Wei, H; Yang, P; Yu, L; Zeng, BH; Zhang, Q; Zhong, CY; Zhu, H | 1 |
| Dhaliwal, S; Galloway, S; Jian, L; Johnsen, R; Mamo, JC; Pallebage-Gamarallage, MM | 1 |
| Atrott, K; Bourayou, R; Dietrich, T; Fleck, E; Graf, K; Gräfe, M; Hucko, T; Jahnke, C; Klein, C; Paetsch, I; Schnackenburg, B; Stawowy, P | 1 |
| Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES | 1 |
| Ashfaq, H; Bregman, DB; Chirinos, JA; Iqbal, N; Khayyam, U; Williams, MM | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O | 1 |
| Arai, H; Matsubara, T; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| Böcking, W; Bramlage, P; Kirch, W; Mueller, EA | 1 |
| Al-Azzawi, HH; Lu, D; Mathur, A; Nakeeb, A; Pitt, HA; Swartz-Basile, DA; Walker, JJ | 1 |
| Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M | 1 |
| Acton, S; Braun, A; Broschat, KO; Krieger, M; Krul, ES; Napawan, N; Stagliano, N; Yesilaltay, A | 1 |
1 review(s) available for ezetimibe and Body Weight
| Article | Year |
|---|---|
[Innovation instead of imitation -- news in drug therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Anticoagulants; Antineoplastic Agents; Azetidines; Body Weight; Cannabinoid Receptor Antagonists; Cetuximab; Drug Therapy; Ezetimibe; Fondaparinux; Humans; Hypoglycemic Agents; Insulin; Osteoporosis, Postmenopausal; Piperidines; Polysaccharides; Pyrazoles; Rimonabant; Smoking Cessation; Teriparatide; Thromboembolism | 2005 |
2 trial(s) available for ezetimibe and Body Weight
| Article | Year |
|---|---|
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant | 2009 |
Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet: a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Azetidines; Body Weight; Diet, Carbohydrate-Restricted; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Simvastatin; Triglycerides | 2010 |
12 other study(ies) available for ezetimibe and Body Weight
| Article | Year |
|---|---|
Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Azetidines; Body Weight; Caco-2 Cells; Cholesterol; Cholesterol, LDL; Cricetinae; Drug Evaluation, Preclinical; Fatty Acids; HEK293 Cells; Humans; Nitric Oxide; Pyrroles; Sulfanilamide; Sulfanilamides; Triglycerides | 2016 |
Ezetimibe increases hepatic iron levels in mice fed a high-fat diet.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Body Weight; Cholesterol; Diet, High-Fat; Ezetimibe; Fatty Acids; Gene Expression; Iron; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2013 |
Ezetimibe impairs uptake of dietary cholesterol oxidation products and reduces alterations in hepatic cholesterol metabolism and antioxidant function in rats.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Azetidines; Body Weight; Cholesterol, Dietary; Ezetimibe; Feces; Lipid Metabolism; Lipids; Liver; Male; Oxidation-Reduction; Rats; Rats, Sprague-Dawley | 2013 |
Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.
Topics: Animals; Azetidines; Body Weight; Cholesterol; Cholesterol Ester Storage Disease; Disease Models, Animal; Ezetimibe; Hepatomegaly; Intestinal Mucosa; Intestines; Liver; Liver Function Tests; Male; Mice; Organ Size; Rats; Sterol Esterase; Triglycerides | 2014 |
Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice.
Topics: Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Bacteria; Bile Acids and Salts; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cytochrome P450 Family 7; Diet, High-Fat; Ezetimibe; Feces; Gene Expression Regulation; Intestinal Absorption; Intestine, Small; Lipid Metabolism; Lipids; Lipoproteins; Liver; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbiota; RNA, Ribosomal, 16S; Steroid Hydroxylases; Up-Regulation | 2015 |
The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-beta abundance.
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Weight; Cholesterol; Cholesterol, Dietary; Enterocytes; Ezetimibe; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intestinal Absorption; Mice; Mice, Inbred C57BL; Pyrroles; Random Allocation; Triglycerides | 2009 |
High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Azetidines; Body Weight; Cholesterol; Disease Models, Animal; Ezetimibe; Magnetic Resonance Angiography; Mice; Mice, Inbred C57BL; Mice, Knockout; Reproducibility of Results; Time Factors | 2009 |
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides | 2010 |
Ezetimibe ameliorates early diabetic nephropathy in db/db mice.
Topics: Adiponectin; Adiposity; Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blotting, Western; Body Weight; Creatinine; Diabetic Nephropathies; Ezetimibe; Glomerular Filtration Rate; Inflammation; Kidney Function Tests; Lipid Metabolism; Male; Metabolism, Inborn Errors; Mice; Mice, Obese; Obesity; Oxidative Stress; Real-Time Polymerase Chain Reaction; Receptors, Adiponectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
Ezetimibe ameliorates cholecystosteatosis.
Topics: Animals; Anticholesteremic Agents; Azetidines; Body Weight; Cholesterol; Cholesterol Esters; Crystallization; Dietary Fats; Ezetimibe; Fatty Acids, Nonesterified; Female; Gallbladder; Gallbladder Diseases; Mice; Mice, Inbred C57BL; Phospholipids; Triglycerides; Ultrasonography | 2007 |
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors | 2007 |
Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Azetidines; Bile Acids and Salts; Body Weight; Cardiomegaly; Cholesterol; Coronary Artery Disease; Cyclic N-Oxides; Disease Models, Animal; Eating; Ezetimibe; Female; Fibrosis; Hypercholesterolemia; Intestinal Absorption; Life Expectancy; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Scavenger Receptors, Class B; Survival Rate; Triglycerides; Tropanes | 2008 |